Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan for the Prevention of Acute GVHD Post Allogeneic HCT
NCT02338232Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Jul 2015
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of telmisartan in graft-versus-host disease (GVHD), sponsored by Hackensack Meridian Health. Primary endpoint: Number of Subjects With Grade 3 or Greater Acute Graft vs. Host Disease at 100 days. Started Jul 2015; status: terminated.
02
Drugs
telmisartan
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02338232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338232.